GlassScriptPhysician profile
Jorge T Go
NPI 1538366729
$14,409.48
in general payments reported to CMS, 2019-2025
43 companies · $3,889 in 2025
The $3,889 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $248 · 2021: $1,411 · 2022: $2,196 · 2023: $2,827 · 2024: $2,732 · 2025: $3,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,438 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,438.09 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,078.63 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,797.31 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,488.95 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,214.17 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $715.83 | 2019-2025 | |
| Madrigal Pharmaceuticals | $547.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $537.46 | 2019-2025 | |
| Qol Medical, LLC | $520.97 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $507.03 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $442.03 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $315.11 | 2019-2024 | Linzess |
| Pfizer INC. | $269.33 | 2019-2025 | |
| Medtronic, INC. | $181.86 | 2025 | Interstim |
| Intercept Pharmaceuticals, INC. | $165.89 | 2022-2024 | |
| Ardelyx, INC. | $140.70 | 2023-2025 | Ibsrela |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $121.27 | 2025 | Nucala |
| Merck Sharp & Dohme LLC | $115.65 | 2019-2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $112.20 | 2021 | |
| Daiichi Sankyo INC. | $103.76 | 2019-2022 | |
| Celltrion USA INC. | $98.07 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $81.13 | 2019-2025 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $79.58 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $78.03 | 2024-2025 | Vowst, Zenpep |
| Ucb, INC. | $76.38 | 2019-2023 | Cimzia |
| Phathom Pharmaceuticals, INC. | $70.37 | 2024-2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $66.28 | 2021-2025 | Monoferric |
| Amgen INC. | $58.06 | 2023 | Avsola, Amjevita |
| Organon LLC | $51.38 | 2022-2025 | Nexplanon, Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $44.64 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $41.70 | 2024-2025 | Iqirvo |
| Novo Nordisk INC | $41.02 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $39.26 | 2023-2024 | Idacio |
| Evoke Pharma, INC. | $34.62 | 2024 | |
| Axonics, INC. | $28.02 | 2023 | Axonics |
| Dova Pharmaceuticals | $22.53 | 2019 | |
| Shionogi INC | $20.19 | 2019 | |
| Shire North American Group INC | $19.71 | 2019 | |
| Tersera Therapeutics LLC | $18.30 | 2022 | |
| Olympus America INC. | $16.00 | 2023 | Evis Exera Lll Colonovideoscope |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $13.66 | 2025 | Suflave, Sutab |
| Micro-Tech Endoscopy USA, INC. | $10.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.